Active drug safety surveillance: a tool to improve public health
- PMID: 18823068
- DOI: 10.1002/pds.1668
Active drug safety surveillance: a tool to improve public health
Abstract
Purpose: Ensuring that drugs have an acceptable safety profile and are used safely is a major public health priority. The Centers for Education and Research on Therapeutics (CERTs) convened experts from academia, government, and industry to assess strategies to increase the speed and predictive value of generating and evaluating safety signals, and to identify next steps to improve the US system for identifying and evaluating potential safety signals.
Methods: The CERTs convened a think tank comprising representatives of the groups noted above to address these goals.
Results: Participants observed that, with the increasing availability of electronic health data, opportunities have emerged to more accurately characterize and confirm potential safety issues. The gain for public health from a highly coordinated network of population-based databases for active surveillance is great and within reach, although operational questions remain. A collaborative network must create a working definition of a safety signal, screening algorithms, and criteria and strategies to confirm or refute a signal once identified through screening. Guidelines are needed for when and how to communicate a signal exists and is being evaluated, as well as the outcome of that evaluation.
Conclusion: A public-private partnership to create a network of government and private databases to routinely evaluate and prioritize safety questions is in the public interest. Better methods are needed, and a knowledgeable workforce is required to conduct the surveillance and understand how to interpret the results. The international community will benefit from the availability of better methods and more experts.
Copyright (c) 2008 John Wiley & Sons, Ltd.
Similar articles
-
Risk assessment of drugs, biologics and therapeutic devices: present and future issues.Pharmacoepidemiol Drug Saf. 2003 Dec;12(8):653-62. doi: 10.1002/pds.859. Pharmacoepidemiol Drug Saf. 2003. PMID: 14762981
-
Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans.Pharmacoepidemiol Drug Saf. 2008 Dec;17(12):1137-41. doi: 10.1002/pds.1642. Pharmacoepidemiol Drug Saf. 2008. PMID: 18763248
-
Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1176-84. doi: 10.1002/pds.1836. Pharmacoepidemiol Drug Saf. 2009. PMID: 19757412
-
The role of data mining in pharmacovigilance.Expert Opin Drug Saf. 2005 Sep;4(5):929-48. doi: 10.1517/14740338.4.5.929. Expert Opin Drug Saf. 2005. PMID: 16111454 Review.
-
The state of dietary supplement adverse event reporting in the United States.Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):962-70. doi: 10.1002/pds.1627. Pharmacoepidemiol Drug Saf. 2008. PMID: 18613260 Review.
Cited by
-
A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review.Drug Saf. 2024 Aug 19. doi: 10.1007/s40264-024-01470-0. Online ahead of print. Drug Saf. 2024. PMID: 39160354
-
Surveillance of Antidepressant Safety (SADS): Active Signal Detection of Serious Medical Events Following SSRI and SNRI Initiation Using Big Healthcare Data.Drug Saf. 2021 Nov;44(11):1215-1230. doi: 10.1007/s40264-021-01110-x. Epub 2021 Sep 8. Drug Saf. 2021. PMID: 34498210 Free PMC article.
-
Circulating liver-specific microRNAs in cynomolgus monkeys.J Toxicol Pathol. 2018 Jan;31(1):3-13. doi: 10.1293/tox.2017-0036. Epub 2017 Sep 8. J Toxicol Pathol. 2018. PMID: 29479135 Free PMC article. Review.
-
Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury.PLoS One. 2017 Feb 22;12(2):e0172463. doi: 10.1371/journal.pone.0172463. eCollection 2017. PLoS One. 2017. PMID: 28225807 Free PMC article.
-
Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data.Osteoporos Int. 2016 Apr;27(4):1653-1658. doi: 10.1007/s00198-015-3402-9. Epub 2015 Nov 11. Osteoporos Int. 2016. PMID: 26558380
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
